Akebia Reports Third Quarter 2020 Financial Results and Recent Business Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/26/2026
- Wall St futures subdued as Nvidia results, inflation take center stage
- Oil drops to more than two-week low on hopes of Hormuz reopening
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Boston Scientific discloses cybersecurity incident causing global disruption
- Wall Street ends higher as tech rebounds before Nvidia results
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Intuit (INTU) Tops Q4 EPS; Offers FY27 Guidance
- Oppenheimer Upgrades Capricor Therapeutics (CAPR) to Outperform 'on Approval Optimism'
Akebia Therapeutics (AKBA) Misses Q3 EPS by 25c
November 5, 2020 8:19 AM ESTAkebia Therapeutics (NASDAQ: AKBA) reported Q3 EPS of ($0.42), $0.25 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $60 million versus the consensus estimate of $84.9 million.
For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.
... More